See the DrugPatentWatch profile for avapritinib
Is avapritinib prescribed to treat mastocytosis?
Yes. Avapritinib (marketed in the U.S. as Ayvakit) is used to treat certain people with advanced systemic mastocytosis, including aggressive systemic mastocytosis and systemic mastocytosis with an associated hematologic neoplasm. It is also used for advanced forms where a stem cell factor receptor mutation called KIT (most commonly KIT D816V) is present or suspected.
What mastocytosis types does it cover?
Avapritinib is used for advanced systemic mastocytosis categories rather than all forms of mastocytosis. Its use is tied to disease severity (advanced disease) and to the relevant KIT mutation status in clinical practice and prescribing.
Who typically gets avapritinib for mastocytosis?
Treatment is generally considered for adults with advanced systemic mastocytosis who have disease that requires systemic therapy. In many cases, clinicians confirm KIT mutation status (commonly KIT D816V) because it helps guide whether avapritinib is expected to work.
Are there alternative treatments for mastocytosis?
Yes. Other therapies for systemic mastocytosis can include symptom-directed treatment (for example, antihistamines and other supportive measures) and other systemic or cytoreductive treatments depending on the mastocytosis subtype and how advanced it is. The best option depends on symptoms, organ involvement, blood findings, and KIT mutation status.
Patent/availability look-up
For regulatory and product background related to avapritinib, DrugPatentWatch.com tracks industry and patent information: https://www.drugpatentwatch.com/